Review of Moxifloxacin Hydrochloride Ophthalmic Solution in the Treatment of Bacterial Eye Infections

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2009 Aug 12

PMID 19668391

Citations 18

Authors

Darlene Miller

Affiliations

Soon will be listed here.

Abstract

Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox((R))) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affinity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gram-negative ocular pathogens.

Citing Articles

Development of sustained-release extemporaneous moxifloxacin loaded commercial soft hydrogel contact lenses.

Pham D, Chomchalao P, Bunneramit K, Kladcharoen P, Khotcharrat R, Tiyaboonchai W Heliyon. 2025; 11(3):e42436.

PMID: 39991249 PMC: 11847108. DOI: 10.1016/j.heliyon.2025.e42436.

Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops.

Drago L Microorganisms. 2024; 12(4).

PMID: 38674593 PMC: 11052454. DOI: 10.3390/microorganisms12040649.

Metabolic Rewiring of upon Drug Treatment and Antibiotics Resistance.

Singha B, Murmu S, Nair T, Rawat R, Sharma A, Soni V Metabolites. 2024; 14(1).

PMID: 38248866 PMC: 10820029. DOI: 10.3390/metabo14010063.

Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Herbert R, Caddick M, Somerville T, McLean K, Herwitker S, Neal T BMJ Open Ophthalmol. 2022; 7(1).

PMID: 36161851 PMC: 9297210. DOI: 10.1136/bmjophth-2022-001002.

Ocular Effects of Glycyrrhizin at Acidic and Neutral pH.

Somayajulu M, McClellan S, Bessert D, Pitchaikannu A, Hazlett L Front Cell Infect Microbiol. 2022; 11:782063.

PMID: 35127554 PMC: 8814321. DOI: 10.3389/fcimb.2021.782063.

References

Mather R, Stewart J, Prabriputaloong T, Wong J, McLeod S . The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol. 2004; 138(4):554-9. DOI: 10.1016/j.ajo.2004.05.011. View

Hooper D . Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001; 7(2):337-41. PMC: 2631735. DOI: 10.3201/eid0702.010239. View

Krasemann C, Meyer J, Tillotson G . Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis. 2001; 32 Suppl 1:S51-63. DOI: 10.1086/319377. View

Domagala J . Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994; 33(4):685-706. DOI: 10.1093/jac/33.4.685. View

Wilhelmus K . Nontuberculous mycobacterial endophthalmitis. Arch Ophthalmol. 2003; 121(11):1663. DOI: 10.1001/archopht.121.11.1663-a. View

Hooper D . Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001; 32 Suppl 1:S9-S15. DOI: 10.1086/319370. View

Stroman D, Dajcs J, Cupp G, Schlech B . In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005; 50 Suppl 1:S16-31. DOI: 10.1016/j.survophthal.2005.06.002. View

Blondeau J . A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. J Antimicrob Chemother. 1999; 43 Suppl B:1-11. DOI: 10.1093/jac/43.suppl_2.1. View

Appelbaum P, Hunter P . The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2001; 16(1):5-15. DOI: 10.1016/s0924-8579(00)00192-8. View

10.

Burka J, Bower K, VanRoekel R, Stutzman R, Kuzmowych C . The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. J Refract Surg. 2007; 23(4):414-7. DOI: 10.3928/1081-597X-20070401-15. View

11.

McCulley J, Caudle D, Aronowicz J, Shine W . Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006; 113(6):955-9. DOI: 10.1016/j.ophtha.2006.01.061. View

12.

Miller D, Alfonso E . Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea. 2004; 23(3):289-93. DOI: 10.1097/00003226-200404000-00012. View

13.

Drlica K, Malik M . Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003; 3(3):249-82. DOI: 10.2174/1568026033452537. View

14.

Oliphant C, Green G . Quinolones: a comprehensive review. Am Fam Physician. 2002; 65(3):455-64. View

15.

Griggs D, Marona H, Piddock L . Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother. 2003; 51(6):1403-7. DOI: 10.1093/jac/dkg241. View

16.

Kampougeris G, Antoniadou A, Kavouklis E, Chryssouli Z, Giamarellou H . Penetration of moxifloxacin into the human aqueous humour after oral administration. Br J Ophthalmol. 2005; 89(5):628-31. PMC: 1772646. DOI: 10.1136/bjo.2004.050054. View

17.

Costello P, Bakri S, Beer P, Singh R, Falk N, Peters G . Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006; 26(2):191-5. DOI: 10.1097/00006982-200602000-00012. View

18.

Smith H, Walters M, Hisanaga T, Zhanel G, Hoban D . Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 2004; 48(10):3954-8. PMC: 521923. DOI: 10.1128/AAC.48.10.3954-3958.2004. View

19.

Donnenfeld E, Kim T, Holland E, Azar D, Palmon F, Rubenstein J . ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusis. J Cataract Refract Surg. 2005; 31(10):2008-11. DOI: 10.1016/j.jcrs.2005.10.030. View

20.

Chaudhry N, Flynn Jr H, Murray T, Tabandeh H, Mello Jr M, Miller D . Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999; 128(4):509-10. DOI: 10.1016/s0002-9394(99)00196-8. View